Suppr超能文献

一种用于增强肝脏保护作用的新型白藜芦醇整体控释系统:纳米制剂研发、药代动力学和药效学

A novel monolithic controlled delivery system of resveratrol for enhanced hepatoprotection: nanoformulation development, pharmacokinetics and pharmacodynamics.

作者信息

Singh Anjali, Ahmad Iqbal, Ahmad Sayeed, Iqbal Zeenat, Ahmad Farhan J

机构信息

a Nanoformulation Research Lab , Jamia Hamdard , New Delhi , India ;

b Department of Pharmaceutical Medicine, Faculty of Pharmacy , Jamia Hamdard , New Delhi , India ;

出版信息

Drug Dev Ind Pharm. 2016 Sep;42(9):1524-36. doi: 10.3109/03639045.2016.1151032. Epub 2016 Mar 9.

Abstract

The current investigation aims to present a novel solid lipid-based nanoparticulate system of resveratrol (RV) for the effective treatment of liver cirrhosis. A simplified solvent injection method was employed and the Box-Behnken experimental design was applied for optimization to get a window particle size of 150-200 nm having maximum entrapment efficiency as well as % release. Optimized resveratrol solid lipid nanoparticles (RV-SLNs) (SR-1) of appropriate characteristics (particle size = 191.1 ± 10.44 nm; zeta potential= -13.56 ± 4.14 mV; entrapment efficiency = 75.23 ± 3.85%; maximum % release = 80.53 ± 3.99%) were produced. Differential scanning calorimetry and X-ray diffraction studies were carried out which collectively proved the reduced crystallinity and stability enhancing the effect of the SLNs. Improved drug stability was further established by the appreciable shelf-life of the formulation from International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)-recommended accelerated stability studies. In vivo studies revealed nearly five-fold increase in the bioavailability of SR-1 (AUC0→∞=3411 ± 170.34 µg/ml/h) as compared to RV suspension (AUC0→∞=653.5 ± 30.10 µg/ml/h). Pharmacodynamic data exhibited a significant decrease in the serum biomarker enzymes (serum glutamic oxalo-acetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) and alkaline phosphatase) after oral administration of RV-SLNs as compared to control and marketed (SILYBON(®)) formulations against paracetamol-induced liver cirrhosis. The effect of the treatment was confirmed by the histopathology of the liver microtome sections. Finally, reverse transcriptase-polymerase chain reaction studies were conducted on isolated liver mRNA from SR-1 treated animals and significant down-regulation of tissue inhibitor of metalloproteinases-1 and nuclear factor-kB was witnessed.

摘要

当前的研究旨在提出一种新型的基于固体脂质的白藜芦醇纳米颗粒系统,用于有效治疗肝硬化。采用了一种简化的溶剂注射方法,并应用Box-Behnken实验设计进行优化,以获得粒径在150-200nm之间、具有最大包封率和释放率的纳米颗粒。制备出了具有合适特性的优化白藜芦醇固体脂质纳米粒(RV-SLNs)(SR-1)(粒径 = 191.1 ± 10.44nm;ζ电位 = -13.56 ± 4.14mV;包封率 = 75.23 ± 3.85%;最大释放率 = 80.53 ± 3.99%)。进行了差示扫描量热法和X射线衍射研究,共同证明了结晶度降低以及稳定性增强,从而提高了固体脂质纳米粒的效果。根据人用药品注册技术国际协调会(ICH)推荐的加速稳定性研究,该制剂可观的保质期进一步证实了药物稳定性的提高。体内研究表明,与白藜芦醇悬浮液(AUC0→∞ = 653.5 ± 30.10μg/ml/h)相比,SR-1的生物利用度提高了近五倍(AUC0→∞ = 3411 ± 170.34μg/ml/h)。药效学数据显示,与对照组和市售(SILYBON(®))制剂相比,口服RV-SLNs后,对乙酰氨基酚诱导的肝硬化患者血清生物标志物酶(血清谷草转氨酶(SGOT)、血清谷丙转氨酶(SGPT)和碱性磷酸酶)显著降低。肝脏切片的组织病理学证实了治疗效果。最后,对SR-1处理动物分离的肝脏mRNA进行了逆转录聚合酶链反应研究,发现金属蛋白酶组织抑制剂-1和核因子-κB显著下调。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验